These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31698561)

  • 1. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
    Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
    Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery.
    Meaney C; Rhebergen S; Kohandel M
    PLoS Comput Biol; 2020 May; 16(5):e1007926. PubMed ID: 32463836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
    Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
    PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 9. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
    Liang D; Miller GH; Tranmer GK
    Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
    Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
    Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
    Smith PJ; McKeown SR; Patterson LH
    IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
    Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
    Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation.
    Forster JC; Marcu LG; Bezak E
    Phys Med; 2019 Aug; 64():145-156. PubMed ID: 31515013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
    Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
    Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.
    Jackson RK; Liew LP; Hay MP
    Clin Oncol (R Coll Radiol); 2019 May; 31(5):290-302. PubMed ID: 30853148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs.
    Mathur S; Chen S; Rejniak KA
    NPJ Syst Biol Appl; 2024 Jan; 10(1):1. PubMed ID: 38182612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
    Anduran E; Dubois LJ; Lambin P; Winum JY
    Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.